<DOC>
	<DOCNO>NCT01632943</DOCNO>
	<brief_summary>This study evaluate efficacy safety renal denervation treatment uncontrolled hypertension . This study enroll minimum 40 maximum 45 subject . The study conduct 8 actively enrol investigational site . The primary endpoint change Office Systolic Blood Pressure baseline 6 month post-procedure .</brief_summary>
	<brief_title>Single-arm Study Symplicity™ Renal Denervation System Patients With Uncontrolled HyperTensioN India</brief_title>
	<detailed_description>Estimated enrollment Start : May 2013 ( estimate 90 day duration ) Estimated last follow-up : September 2013 Follow-Up Duration : Subjects intent-to-treat population follow enrollment 6 month ±14 day effectiveness safety endpoint</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . Individual 18 80 year old time treatment . 2 . Individual receive stable medication regimen include 3 antihypertensive medication different class , one must diuretic expect maintain without change least 6 month . 3 . Individual office systolic blood pressure 160 mm Hg base average 3 blood pressure reading measure screen visit 4 . Individual legally authorize representative agrees study procedure perform , competent willing provide write , inform consent participate clinical study . 1 . Individual renal artery anatomy ineligible treatment include : Main renal artery less 4 mm diameter le 20 mm treatable length Multiple renal artery main renal artery estimate supply less 75 percent kidney . Renal artery stenosis 50 percent renal artery aneurysm either renal artery . A history prior renal artery intervention include balloon angioplasty stenting . 2 . Individual estimate glomerular filtration rate le 45mL per min per 1.73m2 , use MDRD calculation . 3 . Individual 1 inpatient hospitalization hypertensive crisis within past year . 4 . Individual type 1 diabetes mellitus . 5 . Individual 1 episode symptomatic orthostatic hypotension within past year screening process . 6 . Individual require chronic oxygen support mechanical ventilation nocturnal respiratory support sleep apnea . 7 . Individual primary pulmonary hypertension . 8 . Individual know secondary cause hypertension , untreated pheochromocytoma , Cushing 's Disease , coarctation aorta , hyperthyroidism , hyperparathyroidism . 9 . Individual experience myocardial infarction , unstable angina pectoris , syncope , cerebrovascular accident within 6 month screen period , widespread atherosclerosis , document intravascular thrombosis unstable plaque . 10 . Individual schedule plan surgery cardiovascular intervention next 6 month . 11 . Individual condition would prohibit interfere ability obtain accurate blood pressure measurement use protocol specify automatic blood pressure monitor 12 . Individual severe cardiac valve stenosis , opinion Investigator , significant reduction blood pressure contraindicate . 13 . Individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study 14 . Individual pregnant , nurse planning pregnant . 15 . Individual known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , would unlikely unable comply study followup requirement . 16 . Individual currently enrol another investigational drug device trial . For purpose protocol , participant involve extended followup trial product investigational currently commercially available consider enrol investigational trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uncontrolled Hypertension</keyword>
</DOC>